Develops an antibody drug candidate to treat autoimmune diseases driven by harmful antibodies.
10-K for FY2026, filed May 20, 2026
No revenue reported yet.
10-K for FY2024, filed May 29, 2024
10-Q for Q2 FY2027, filed Nov 9, 2026
−$97.2MView ↗
Narrower development focus
The older report described development of both antibody candidates; the latest report says Immunovant discontinued development of its first candidate across indications and is focusing on the other.
10-K for FY2023, filed May 22, 2023 10-K for FY2026, filed May 20, 2026In April 2026, we announced top-line results from two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for…View ↗
Competes with Argenx, Johnson & Johnson, UCB, Viridian Therapeutics, AstraZeneca, Amgen, Sanofi, Dianthus, Crinetics Pharmaceuticals, Lycia Therapeutics, Biohaven, Merida Biosciences, Yarrow Bioscience, Biogen, and Merck
10-K for FY2026, filed May 20, 2026We expect to face intense competition from other biopharmaceutical companies who are developing agents for the treatment of autoimmune…View ↗
Loading...